(CercleFinance.com) – Pharmaceutical companies Janssen of Johnson & Johnson announce that they have applied to the United States Food and Drug Administration (FDA) via a biological license application (BLA) to obtain approval for teclistamab, an antibody Ready-to-use experimental bispecific, for the treatment of patients with relapsed or refractory multiple myeloma (R / R).
‘Despite all the advances in the treatment of multiple myeloma, the unmet need is still very high. Our relentless pursuit of treatments for this disease continues with the same sense of urgency we always had, ‘said Peter Lebowitz, Global Therapeutic Area Head, Oncology, at Janssen Research & Development.
Multiple myeloma is an incurable cancer of the blood that affects the white blood cells in the bone marrow.
Copyright © 2021 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
